Facing the treatment cost of thousands of yuan per box for the original apalutamide in China, the apalutamide generic APADX launched by Laos Big Bear Pharmaceutical offers a more affordable treatment option for prostate cancer patients with limited financial resources, improving accessibility.
Is there a Laos generic version of apalutamide?
Yes, there is a Laos generic version of apalutamide. The Laos Big Bear version of apalutamide is available in the specification of 60mg*120 tablets per box. For more questions, we recommend you contact our professional customer service for detailed consultation.
Indications and therapeutic positioning of apalutamide
Apalutamide (Erleada®, apalutamide) is an oral androgen receptor inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). This patient population is characterized by persistently rising serum prostate-specific antigen (PSA) levels, confirmed absence of distant metastatic lesions by imaging studies (such as bone scan, CT, or MRI), and ongoing medical or surgical castration (serum testosterone<50 ng="">
Recommended dosage and administration of apalutamide
The recommended dose of apalutamide is 240 mg (four 60 mg film-coated tablets) taken orally once daily at approximately the same time each day (e.g., every morning). It may be taken with or without food, but tablets must be swallowed whole and should not be chewed, crushed, or split. If a dose is missed, it should be taken as soon as remembered; if the next scheduled dose is within 12 hours, the missed dose should be skipped and the regular schedule resumed. Do not double the dose to make up for a missed one. During treatment, concurrent androgen deprivation therapy (e.g., GnRH agonist/antagonist subcutaneous or intramuscular injection, or prior surgical castration) must be continued to maintain sustained suppression of peripheral androgen levels. For ≥grade 3 toxicity or intolerable adverse reactions (per CTCAE grading), treatment interruption is recommended until symptoms resolve to ≤grade 1 or baseline, after which resumption at the original dose may be considered; if severe toxicity recurs, dose reduction to 180 mg (3 tablets daily) or 120 mg (2 tablets daily) should be implemented with close monitoring of tolerability. After dose adjustment, the dose should not be increased back to the higher level, and the reduced regimen should be individualized, determined by the attending physician based on the patient's hepatic and renal function, performance status, and concomitant medications.
